MEDI8852

01/01/2017 - "Additionally, MEDI8852 blocked influenza transmission in ferrets, a unique finding among influenza-specific mAbs."
01/01/2019 - "FY1 and an optimized version, MEDI8852, anti-influenza HA mAbs, have been shown to neutralize influenza virus during singular influenza infection. "
11/01/2018 - "The safety profile of MEDI8852 supports its continued development for treatment of patients hospitalized with influenza A infection. "
11/01/2017 - "A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers."
11/01/2018 - "Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza."

01/01/2017 - "MEDI8852 was administered to mice and ferrets by intraperitoneal injection at varying doses, 24 hours prior to intranasal infection with H5N1 and H7N9 viruses for prophylaxis, and 24, 48, and 72 hours post-infection for treatment. "
01/01/2019 - "FY1 and an optimized version, MEDI8852, anti-influenza HA mAbs, have been shown to neutralize influenza virus during singular influenza infection. "
11/01/2018 - "The safety profile of MEDI8852 supports its continued development for treatment of patients hospitalized with influenza A infection. "
01/01/2017 - "MEDI8852 alone was effective treatment for lethal H5N1 infection in ferrets compared to oseltamivir and R347, and MEDI8852 plus oseltamivir was better than oseltamivir alone. "
01/01/2017 - "MEDI8852 was effective for prophylaxis and treatment of H7N9 and H5N1 infection in mice, with a clear dose-dependent response and treatment with MEDI8852 24, 48, or 72 hours postinfection was superior to oseltamivir for H5N1. "

11/01/2018 - "Nasopharyngeal samples were collected through day 7 for confirmation of influenza A infection, viral shedding, and oseltamivir and MEDI8852 susceptibility. "